An anti-GDF15 monoclonal antibody, ponsegromab, was recently shown to ameliorate cachexia caused by non-small cell lung cancer and pancreatic cancer 62, and CLIA-certified assays exist for measuring PTHrP and GDF15 in plasma. Here, GDF15 is linked to non-small cell lung carcinoma.